GSK gets CDSCO marketing authorization for Rotavirus Vaccine, Live Attenuated, Oral IP
New Delhi: The pharmaceutical major, GlaxoSmithKline Pharmaceuticals Limited, has recently received a grant of marketing authorization for Rotavirus Vaccine (Live Attenuated, Oral) IP from the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO).
This came in the wake of the proposal presented by GlaxoSmithKline Pharmaceuticals for the grant of Marketing Authorization of Rotavirus Vaccine (Live Attenuated, Oral) IP in India along with the Phase III clinical study results.
The rotavirus vaccination is a live attenuated (weakened) liquid frozen vaccine that stimulates the immune system to create antibodies (proteins) without actually infecting the child. These antibodies protect against rotavirus-induced diarrhoea in the case of infection. Rotavirus infection is a highly infectious sickness caused by a virus that transmits quickly from child to child, primarily affecting babies and young children.
Also Read:Rotavirus vaccination reduces hospitalizations and mortality in infants
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.